HYDROCORTISONE ACETATE

Manufacturer
GRAXCELL PHARMACEUTICAL, LLC.
Effective date
2021-12-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
13
Source
full-release
Hydrated at
2026-05-31 20:38:41

Label at a glance#

ProductHYDROCORTISONE ACETATE
Active ingredientHYDROCORTISONE ACETATE
Label structure12 sections

Storage and handling

Store at 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature]. Store away from heat. Protect from freezing. Manufactured for: Graxcell pharmaceutical, LLC. 130 knickerbocker ave,Bohemia, NY 11716 Manufactured by: Graxcell pharmaceutical, llc. 136 OAk Drive, syosset, NY 11791 1-888-266-8818.

Label contents#

Full prescribing information#

Graxcell Pharmaceutical, llc. Disclaimer: This drug has not been found by FDA to be safe and effective, and this labelling has not been approved by FDA. Hydrocortisone acetae, 25mg. Rectal suppositories.

DESCRIPTION SECTION

hydro structural formulahydro structural formula

Hydrocortisone Acetate is a corticosteroid designated chemically as pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy-(11β) with the following structural formula:

Each rectal suppository contains hydrocortisone acetate, USP 25 mg in a specially blended hydrogenated vegetable oil base

CLINICAL PHARMACOLOGY SECTION

In normal subjects, about 26% of hydrocortisone acetate is absorbed when the suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasconstrictive action.

INDICATIONS & USAGE SECTION

Hydrocortisone acetate suppositories are indicated for the use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and puritus ani.

CONTRAINDICATIONS SECTION

Hydrocortisone Acetate suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components

PRECAUTIONS SECTION

Do not use unless adequate proctologic examination is made. If irritation develops, the product should be discontinued and appropriate therapy instituted. In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Carcinogenic: No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

ADVERSE REACTIONS SECTION

The following local adverse reactions have been reported with hydrocortisone acetate suppositories; burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.

To report suspected adverse reactions, contact

Graxcell pharmaceutical, llc.

1-888-266-8818 or

FDA @ 1-800-FDA-1088 or

www.fda.gov/medwatch

OVERDOSAGE SECTION

If signs and symptoms of systemic overdosage occur, discontinue use.

DOSAGE & ADMINISTRATION SECTION

suppo 2suppo 2

Usual Dosage: One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily: or two suppositories twice daily. In factitial proctitis, recommended therapy in six to eight weeks or less, according to the response of the individual case.

Rx only.

OPENING INSTRUCTIONS

Avoid excessive handling of the suppository. It is designed to melt at body temperature.

1. Separate plastic film at top opening and pull downward.

2. Continue pulling downward to almost the full length of the suppository.

3. Gently remove the suppsitory from the film pocket.

HOW SUPPLIED SECTION

Hydrocortisone Acetate suppositories 25mg are white,cyclinder shaped, with one end tapered.

Package of 12 NDC 70795-2412-1

and

Package of 24 NDC 70795-2412-2

STORAGE AND HANDLING SECTION

Store at 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature]. Store away from heat. Protect from freezing.

Manufactured for:

Graxcell pharmaceutical, LLC.

130 knickerbocker ave,Bohemia, NY 11716

Manufactured by:

Graxcell pharmaceutical, llc.

136 OAk Drive,

syosset, NY 11791

1-888-266-8818.

DRUG ABUSE AND DEPENDENCE SECTION

Drug abuse and dependece have not been reported in patients treated with Hydrocortisone acetate suppositories.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Hydrocortisone Acetate 24ctHydrocortisone Acetate 24ct

Hydrocortisone Acetate 12ctHydrocortisone Acetate 12ct

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1291082hydrocortisone acetate 25 MG Rectal SuppositoryPSN13
1291082hydrocortisone acetate 25 MG Rectal SuppositorySCD13

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
HYDROCORTISONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
15bd4439-874a-4934-9954-248e5455d460Product name120260310
9962b773-9f2e-22cc-0032-535e48ac417bProduct name320250724
56bb0587-1bf2-48b2-9d93-fc9f59d1eeb2Product name120250325
4d56e8eb-d741-d4a5-de3f-2bab1af75a60Product name720220608
626d7260-31b5-4412-84fd-579746adb6b3Product name120210513
8a011600-5e61-4c59-ab7b-54ab658a3b71Product name220181127
a919621a-248d-3c7a-1084-9f9ce286fdfdProduct name220181009
e7d5a174-836b-a0af-b014-cb0826c69ddcProduct name220181004
fcce390d-6460-4701-87cf-940d8800a1c3Product name220180212
bf065fa6-1e3b-e4c3-0bde-2dc842ceeea1Product name220150218
02657a3f-1489-66ea-f740-5ab9524e57d7Product name120140508
26f3d783-2cc1-4327-e77d-71804cf675a2Product name120140508
36fdc54c-bbeb-981e-8a53-4d768e283892Product name120140508
58f3f9b7-3b9b-a9c1-1c9f-18ac777192b8Product name120140508
61e59a42-186b-9f4b-aec3-fb49a6debc31Product name120140508
705740e1-dee5-2610-c5a3-4c59cd9d62afProduct name120140508
7bdc4804-3832-c0df-e519-72b6d47c9792Product name120140508
a7051cba-790b-a699-81f8-dbbbdbd9b5acProduct name120140508
abaf203f-619e-f265-559f-8c81af5cb1c2Product name120140508
acc4d8bb-0e29-e9f8-65f8-31e94184a9c0Product name120140508
b045ad64-0f28-9a02-2f9b-b34d94fb2278Product name120140508
bfd28ffb-d550-3fe9-f65b-10bcb7f971fdProduct name120140508
da108d9e-edc8-17a3-8c28-3251c6a8acccProduct name120140508
fe21f3fd-a378-0654-1972-db3c3b64470eProduct name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70795-2412-1HYDROCORTISONE ACETATE12 in 1 CARTONSUPPOSITORY1213
70795-2412-2HYDROCORTISONE ACETATE24 in 1 CARTONSUPPOSITORY2413

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
70795-2412HYDROCORTISONE ACETATE SUPPOSITORY [GRAXCELL PHARMACEUTICAL, LLC.]13Legacy NDC, 2 package rows20211222_3abf5256-0bcf-0c2c-e054-00144ff88e88.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70795-2412-1EA - Each70795-2412a71b7da2-70a4-4c63-a768-5d65805446d012018-09-05
70795-2412-2EA - Each70795-2412d7013cab-97fa-4e8e-8e97-fb9829883e2112016-10-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70795-241270795-2412-1, 70795-2412-2

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
d3adadb0-19cb-617e-e053-2a95a90a49213abf5256-0bcf-0c2c-e054-00144ff88e882021-12-21Adverse reactionsExact identifier
spl id: d3adadb0-19cb-617e-e053-2a95a90a4921
spl set id: 3abf5256-0bcf-0c2c-e054-00144ff88e88

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.